Beone Medicines Ltd.(688235)

287.30-5.17-1.77%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- CICC Hong Kong Stock Connect and Hang Seng Index Adjustment Preview: Zijin Gold Intl (02259) Among Potential Hang Seng Index Additions; 44 Companies Expected to Enter Stock Connect
  Stock News · 01-19
  CICC Hong Kong Stock Connect and Hang Seng Index Adjustment Preview: Zijin Gold Intl (02259) Among Potential Hang Seng Index Additions; 44 Companies Expected to Enter Stock Connect
- Hong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide
  Stock News · 01-14
  Hong Kong Stock Movement | BEIGENE (06160) Opens Over 3% Higher, Announces Commercial Launch of Baiyueda® in China, First Batch to Cover 70 Cities Nationwide
- BeOne Medicines Showcases Global Oncology Leadership at J.P. Morgan Healthcare Conference
  Reuters · 01-13
  BeOne Medicines Showcases Global Oncology Leadership at J.P. Morgan Healthcare Conference
- Beone Medicines : Bernstein Raises to Outperform From Market-Perform; Raises Target Price to $414 From $362
  THOMSON REUTERS · 01-12
  Beone Medicines : Bernstein Raises to Outperform From Market-Perform; Raises Target Price to $414 From $362
- Beone Medicines : RBC Raises Target Price to $417 From $408
  THOMSON REUTERS · 01-08
  Beone Medicines : RBC Raises Target Price to $417 From $408
- China's Biopharma Sector Enters New Year On A high
  Benzinga_recent_news · 01-08
  China's Biopharma Sector Enters New Year On A high
- BEIGENE (06160) Awards Total of 53,300 Restricted Stock Units in American Depositary Shares
  Stock News · 01-07
  BEIGENE (06160) Awards Total of 53,300 Restricted Stock Units in American Depositary Shares
- BeOne Medicines AG Grants 53,322 RSUs Under Amended Incentive Plan
  Reuters · 01-07
  BeOne Medicines AG Grants 53,322 RSUs Under Amended Incentive Plan
- BeOne Medicines Reports Positive Phase 3 Results for ZIIHERA Plus TEVIMBRA in First-Line HER2+ GEA
  Reuters · 01-07
  BeOne Medicines Reports Positive Phase 3 Results for ZIIHERA Plus TEVIMBRA in First-Line HER2+ GEA
- China Approves BeOne Medicines' Sonrotoclax for Relapsed/Refractory MCL and CLL/SLL
  Reuters · 01-06
  China Approves BeOne Medicines' Sonrotoclax for Relapsed/Refractory MCL and CLL/SLL
- BEIGENE's BCL-2 Inhibitor "Sotokela" Approved for Market Launch
  Deep News · 01-05
  BEIGENE's BCL-2 Inhibitor "Sotokela" Approved for Market Launch
- Health Canada Approves Tevimbra® (Tislelizumab for Injection) in Combination With Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
  THOMSON REUTERS · 2025-12-23
  Health Canada Approves Tevimbra® (Tislelizumab for Injection) in Combination With Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
- BeOne Medicines to Present at J.P. Morgan Healthcare Conference
  Reuters · 2025-12-23
  BeOne Medicines to Present at J.P. Morgan Healthcare Conference
- BeOne Medicines Secures New Financing Facility with HSBC-Led Lenders
  Reuters · 2025-12-19
  BeOne Medicines Secures New Financing Facility with HSBC-Led Lenders
- BeOne Medicines AG Awards Dr. Lai Wang $10 Million Equity Grant and $750,000 Salary as President of R&D
  Reuters · 2025-12-18
  BeOne Medicines AG Awards Dr. Lai Wang $10 Million Equity Grant and $750,000 Salary as President of R&D
- FDA Grants Fast Track Designation to BeOne Medicines' BGB-B2033 for Liver Cancer
  Reuters · 2025-12-18
  FDA Grants Fast Track Designation to BeOne Medicines' BGB-B2033 for Liver Cancer
- Beone Medicines Granted U.S. FDA Fast Track Designation for Bgb-B2033 as Treatment for Hepatocellular Carcinoma
  THOMSON REUTERS · 2025-12-18
  Beone Medicines Granted U.S. FDA Fast Track Designation for Bgb-B2033 as Treatment for Hepatocellular Carcinoma
- Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE
  Deep News · 2025-12-15
  Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE
- BeOne Medicines Reports 74% Six-Year Progression-Free Survival with BRUKINSA in Treatment-Naïve CLL
  Reuters · 2025-12-08
  BeOne Medicines Reports 74% Six-Year Progression-Free Survival with BRUKINSA in Treatment-Naïve CLL
- BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025
  Reuters · 2025-12-08
  BeOne Medicines AG Reports Promising Sonrotoclax Results in B-Cell Malignancies at ASH 2025
Company Profile
Company Name
百济神州有限公司
Industry
医药制造业
Listing Date
2021-12-15
Registered Capital
15万元
Introduction
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。

1D
5D
Day
Week
Month

Loading ...

High

295.86

Open

295.00

T/O Rate

1.76%

Low

285.00

292.47

Amplitude

3.71%

To The Moon

Beone Medicines Ltd.(688235)

Company Profile

Most Discussed